Guillain-Barré Syndrome

Results from a phase 2 clinical trial showed that treatment with an IgG-cleaving enzyme for individuals diagnosed with Guillain-Barré syndrome led to faster muscle strength recovery and mobility.

Survey results that showed that only 52% of adults in the United States plan to get the vaccine for this flu season and the FDA’s approval of a vaccine for smallpox and monkeypox were among to top stories in infectious disease last week.